Clinical trial
A Non-interventional, Post-authorization Safety Study of Patients With Relapsed or Refractory Mantle Cell Lymphoma to Further Investigate and Characterize the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden
NCT03647124 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Non-interventional, Post-authorization Safety Study of Patients With Relapsed or Refractory Mantle Cell Lymphoma to Further Investigate and Characterize the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden
- Lead sponsor
- Celgene
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 13, 2019
- Completion date
- January 10, 2024
- Enrollment
- 105 (actual)
- Sites
- 79
Conditions
As the registry lists them; a condition with its own page is linked.